UnitedHealth $UNH rose around 8% after Q2 adjusted EPS of $6.38 and revenue of $112.0B topped expectations. The company lifted 2026 adjusted EPS guidance to $19.50-$20.00 and reported an 86.7% medical cost ratio, easing managed-care margin concerns.
Eli Lilly agreed to acquire AtaiBeckley for $6.75 a share in cash, valuing the upfront consideration at about $2.8B. A CVR could add up to $2.50 a share, or about $1.0B, tied to BPL-003 and VLS-01 milestones.
Blackstone and TPG are seeking more than $4B for Hologic’s surgical unit, the Financial Times reported. The carve-out would help pay down debt and return cash after the firms’ $18.3B buyout of Hologic.
Bio-Techne $TECH traded about 20% higher after Merck KGaA agreed to buy the company for $73 a share in cash, valuing it at about $11.3B. The offer is 36% above Bio-Techne's one-month VWAP and is expected to close in late 2026 or early 2027, subject to approvals.
Eli Lilly $LLY moved higher after reports that the company plans nearly $4B of vaccine acquisitions. The planned deals clear the Tier-1 M&A threshold and extend Lilly’s GLP-1 cash flow into infectious-disease assets.
Jardine Matheson agreed to buy 100% of I-MED Radiology Network at an AUD3.4B ($2.4B) enterprise value. The price equals roughly 11.5x projected adjusted EBITDA for the year ending June 2026, with cash and debt funding and 2026 EPS guidance unchanged.
The FDA has launched a first-of-its-kind pilot using cloud-based causal AI to shorten drug and medical device clinical trial timelines by 20–40%. FDA Chief AI Officer Jeremy Walsh says the approach could also accelerate regulatory approval timelines.
Google DeepMind introduced the AI co-clinician, a multimodal AI agent research initiative to support healthcare workers. In blind evaluations, the system achieved zero critical errors in 97 of 98 primary care queries and matched physician-level performance on medication knowledge benchmarks.
A Harvard Medical School trial found OpenAI's o1 reasoning model correctly diagnosed 67% of ER patients, beating human physicians at 50-55%. With more clinical data, o1 reached 82% accuracy and dominated long-term treatment planning at 89% versus doctors' 34%.
A peer-reviewed study published in Science tested OpenAI's o1 on 76 real ER triage cases and found it achieved exact or near-exact diagnoses 67% of the time, versus 55% and 50% for two attending physicians who received identical patient data.
A new study published in Science found that a state-of-the-art LLM matched or exceeded human emergency physicians in diagnostic choices, emergency triage, and next-step management decisions using real ER data and hundreds of physician comparisons. Researchers say the results call for collaborative care models, not AI replacement of doctors.
$LLY rose more than 10% after Eli Lilly posted Q1 revenue of $19.8 billion, adjusted EPS of $8.55, and lifted its 2026 sales outlook by $2 billion.